HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2011 | 925 | 1175 | 78.7% | |
| HF 4 | 2012 | 1007 | 1210 | 83.2% | |
| HF 4 | 2013 | 1086 | 1268 | 85.7% | |
| HF004 | 2014 | 409 | 472 | 86.7% | |
| HF004 | 2015 | 446 | 499 | 89.4% | |
| HF004 | 2016 | 617 | 715 | 86.3% | |
| HF004 | 2017 | 784 | 900 | 87.1% | |
| HF004 | 2018 | 1028 | 1208 | 85.1% | |
| HF004 | 2019 | 1170 | 1347 | 86.9% | |
| HF004 | 2020 | 1385 | 1578 | 87.8% | |
| HF006 | 2021 | 1882 | 2134 | 88.2% | |
| HF006 | 2022 | 2082 | 2176 | 95.7% | |
| HF006 | 2023 | 2638 | 2755 | 95.8% |
